𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combination low-dose lymphoblastoid interferon and thymosin α1 therapy in the treatment of chronic hepatitis B

✍ Scribed by G. Rasi; M. G. Mutchnick; D. Di Virgilio; P. Sinibaldi-Vallebona; P. Pierimarchi; F. Colella; C. Favalli; E. Garaci

Book ID
115076186
Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
527 KB
Volume
3
Category
Article
ISSN
1352-0504

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term outcomes of thymosin-α1 and in
Long-term outcomes of thymosin-α1 and interferon α-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B
✍ Murat Saruc; Nuri Ozden; Nurten Turkel; Semin Ayhan; Lynette M. Hock; Isil Tuzcu 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB 👁 1 views

Hepatitis B e antibody (HbeAb) and hepatitis B virus (HBV) DNA positive chronic hepatitis is a clinical entity, distinct from classical hepatitis B e antigen (HbeAg) positive chronic hepatitis B. Our aim was to evaluate the long-term therapeutic efficacy of the combination of interferon alpha-2b and

Combination therapy with thymosin α1 and
Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial
✍ Kenneth E. Sherman; Maria Sjogren; Robin L. Creager; Melissa A. Damiano; Stephen 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 1 views

Hepatitis C is a major cause of liver disease leading to cirrhosis. Although interferon (IFN) is the only approved therapy, treatment is characterized by low response rates and dose-limiting side effects. We evaluated the addition of thymosin ␣1 (TA1), an immunomodulatory peptide, to the standard tr